Becton, Dickinson and Company $BDX Shares Sold by Park National Corp OH

Key Points

• Park National Corp OH reduced its Becton, Dickinson and Company stake by 18.3% in the third quarter, selling 10,859 shares and retaining 48,535 shares valued at approximately $8.7 million. Institutional investors collectively own 86.97% of BDX.
• Analyst sentiment remains mixed, with eight Buy ratings and nine Hold ratings; the stock has an average rating of Hold and an average price target of $187.67.
• BDX exceeded quarterly earnings and revenue expectations, reporting $3.23 in adjusted EPS and $4.98 billion in revenue, while maintaining fiscal 2026 EPS guidance of $12.62–$12.72. The company also pays a quarterly dividend of $1.05, yielding about 2.3%.

Park National Corp OH cut its holdings in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 18.3% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 48,535 shares of the medical instruments supplier's stock after selling 10,859 shares during the period. Park National Corp OH's holdings in Becton, Dickinson and Company were worth $8,688,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. TD Waterhouse Canada Inc. grew its position in shares of Becton, Dickinson and Company by 17.1% during the second quarter. TD Waterhouse Canada Inc. now owns 96,211 shares of the medical instruments supplier's stock worth $14,715,000 after acquiring an additional 14,077 shares during the last quarter. Northside Capital Management LLC grew its holdings in Becton, Dickinson and Company by 18.3% in the 2nd quarter. Northside Capital Management LLC now owns 61,324 shares of the medical instruments supplier's stock worth $9,280,000 after buying an additional 9,494 shares in the last quarter. NewEdge Advisors LLC raised its stake in Becton, Dickinson and Company by 35.0% during the 1st quarter. NewEdge Advisors LLC now owns 44,032 shares of the medical instruments supplier's stock valued at $6,923,000 after acquiring an additional 11,414 shares in the last quarter. Beverly Hills Private Wealth LLC bought a new position in shares of Becton, Dickinson and Company in the second quarter worth $3,353,000. Finally, Wealthfront Advisers LLC acquired a new position in shares of Becton, Dickinson and Company during the second quarter valued at $2,567,000. Institutional investors and hedge funds own 86.97% of the company's stock.

Insiders Place Their Bets

In related news, CEO Thomas E. Polen, Jr. sold 4,152 shares of the company's stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $185.00, for a total value of $768,120.00. Following the completion of the sale, the chief executive officer owned 110,163 shares of the company's stock, valued at approximately $20,380,155. This represents a 3.63% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Feld sold 165 shares of Becton, Dickinson and Company stock in a transaction dated Wednesday, August 26th. The stock was sold at an average price of $188.49, for a total transaction of $31,100.85. Following the transaction, the executive vice president directly owned 19,720 shares in the company, valued at $3,717,022.80. This trade represents a 0.83% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 6,906 shares of company stock valued at $1,265,855 in the last 90 days. 0.40% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on BDX. Royal Bank Of Canada lifted their price target on Becton, Dickinson and Company from $180.00 to $190.00 and gave the company a "sector perform" rating in a research report on Thursday, August 13th. Evercore set a $180.00 price objective on shares of Becton, Dickinson and Company in a research report on Monday, July 6th. Bank of America boosted their target price on shares of Becton, Dickinson and Company from $185.00 to $200.00 and gave the stock a "neutral" rating in a report on Monday, August 31st. TD Cowen lifted their price target on shares of Becton, Dickinson and Company from $163.00 to $182.00 and gave the stock a "hold" rating in a research report on Wednesday, August 5th. Finally, Citigroup reissued a "buy" rating on shares of Becton, Dickinson and Company in a research note on Thursday, August 13th. Eight research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat, Becton, Dickinson and Company currently has an average rating of "Hold" and an average price target of $187.67.

Becton, Dickinson and Company Stock Performance

Becton, Dickinson and Company stock traded up $2.61 during midday trading on Monday, hitting $179.41. 478,562 shares of the company were exchanged, compared to its average volume of 2,505,086. The business has a fifty day simple moving average of $180.69 and a two-hundred day simple moving average of $161.72. Becton, Dickinson and Company has a fifty-two week low of $127.59 and a fifty-two week high of $193.07. The firm has a market capitalization of $49.43 billion, a PE ratio of 54.03, a price-to-earnings-growth ratio of 11.92 and a beta of 0.21. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.51 and a current ratio of 0.87.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share for the quarter, beating analysts' consensus estimates of $3.14 by $0.09. The company had revenue of $4.98 billion during the quarter, compared to analysts' expectations of $4.89 billion. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The firm's revenue for the quarter was up 5.4% on a year-over-year basis. During the same quarter in the previous year, the company earned $3.68 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. On average, sell-side analysts forecast that Becton, Dickinson and Company will post 12.67 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 9th were given a $1.05 dividend. This represents a $4.20 annualized dividend and a dividend yield of 2.3%. The ex-dividend date was Wednesday, September 9th. Becton, Dickinson and Company's dividend payout ratio (DPR) is 126.51%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company, doing business as BD, is a global medical technology company that develops, manufactures and sells devices, diagnostic products and solutions for healthcare providers, researchers and patients. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, the company serves customers in hospitals, laboratories, physician offices, pharmacies and other healthcare settings worldwide.

BD's Medical segment offers products used for medication delivery and management, including needles, syringes, infusion systems, medication preparation and dispensing technologies, and systems designed to help improve medication safety.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.